Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.67 |
| ▸ | JAK3 | P52333 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21139931 | 1.00 | KMO (0.67) | KMOJAK3DRD2DRD3PRMT5 | |
| SCHEMBL19465286 | 0.92 | KMO (0.69) | KMODRD2DRD3 | |
| SCHEMBL1633310 | 0.90 | KMO (0.71) | KMOHTR2C | |
| Hydrochloric Acid SCHEMBL6709116 | 0.89 | KMO (0.69) | KMOHTR2C | |
| SCHEMBL13406411 | 0.88 | KMO (0.72) | KMODRD2DRD3HTR2C | |
| SCHEMBL13406410 | 0.88 | KMO (0.72) | KMODRD2DRD3HTR2C | |
| SCHEMBL30344892 | 0.86 | PARP1 (0.53) | KMOJAK3DRD2DRD3PRMT5 | |
| Hydrochloric Acid SCHEMBL28155975 | 0.85 | PARP1 (0.51) | KMOJAK3DRD2DRD3PRMT5 | |
| Hydrochloric Acid SCHEMBL28155974 | 0.85 | PARP1 (0.51) | KMOJAK3DRD2DRD3PRMT5 | |
| SCHEMBL347728 | 0.82 | HTR2C (0.48) | JAK3HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062322-A1 | Novel Tricyclic Spiropiperidines or Spiropyrrolidines | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| US-20090048238-A1 | NOVEL BIARYL DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-02-19 | — | — | US | disclosed |
| US-7449475-B2 | Tricyclic spiropiperidines or spiropyrrolidines | ASTRAZENECA AB (SE) | 2008-11-11 | — | — | US | disclosed |
| EP-1521757-B1 | TRICYCLIC SPIROPIPERIDINES OR SPIROPYRROLIDINES | ASTRAZENECA AB (SE) | 2008-01-30 | — | — | EP | disclosed |
| US-20050245741-A1 | Novel tricyclic spiropiperidines or spiropyrrolidines | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062322-A1 | Novel Tricyclic Spiropiperidines or Spiropyrrolidines | REN, TACR1, AGTR1 | KMO 4484/4885JAK3 4019/4885DRD2 20/4885 |
| US-20050245741-A1 | Novel tricyclic spiropiperidines or spiropyrrolidines | REN, TACR1, AGTR1 | KMO 4529/4885JAK3 4095/4885DRD2 22/4885 |
| US-20090048238-A1 | NOVEL BIARYL DERIVATIVES | CCR3, CCRL2, CCR2 | KMO 1845/4885JAK3 667/4885DRD2 505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.